Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."

With digital twins for drug testing and local 3D printing of drugs, pharma's role could shift from mass manufacturing to licensing molecule formulas. A doctor would test a drug on a digital twin and a pharmacy would print the personalized dose on site.

For future outbreaks, it's possible to deploy self-contained, mobile manufacturing units on skids or wheels. These modules would house both upstream and downstream processes, allowing them to be shipped directly to a location, plugged in, and activated for rapid, localized production of vaccines or therapeutics without needing fixed infrastructure.

Unlike traditional pharmaceuticals, cell therapies are patient-specific (one batch, one patient). This makes the centralized global manufacturing model inefficient. A decentralized, local production network is essential for global accessibility and scalability, fundamentally changing the supply chain strategy.

The ultimate vision is to move beyond generalized treatments to truly individualized medicine. This involves understanding the complete causal chain from a person's unique genetic variants to the resulting protein behavior and disease. With this mechanistic understanding, it becomes possible to design a bespoke drug for that specific individual.

For patients with ultra-rare diseases, traditional drug development is too slow. AI platforms like Therna's can design a custom RNA molecule in days and complete the lab-testing cycle in under three months, compressing a multi-year process and making previously impossible treatments viable.

Many innovative drug designs fail because they are difficult to manufacture. LabGenius's ML platform avoids this by simultaneously optimizing for both biological function (e.g., potency) and "developability." This allows them to explore unconventional molecular designs without hitting a production wall later.

Dr. Crowe believes AI's most immediate impact isn't designing new antibodies from scratch. Instead, it's analyzing vast datasets to predict which newly discovered antibodies are developable (stable, high-expression), preventing investment in potent molecules that ultimately can't be manufactured at scale.

The ideal future for personalized cell therapies involves decentralized manufacturing using mobile units at the point of care, like a hospital. This model, which Cellino is pioneering with Mass General Hospital, eliminates complex logistics, reduces costs, and broadens patient access beyond major urban centers to rural areas.